JP2020522566A5 - - Google Patents

Download PDF

Info

Publication number
JP2020522566A5
JP2020522566A5 JP2020514147A JP2020514147A JP2020522566A5 JP 2020522566 A5 JP2020522566 A5 JP 2020522566A5 JP 2020514147 A JP2020514147 A JP 2020514147A JP 2020514147 A JP2020514147 A JP 2020514147A JP 2020522566 A5 JP2020522566 A5 JP 2020522566A5
Authority
JP
Japan
Prior art keywords
synthetic polynucleotide
composition
seq
synthetic
end cap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020514147A
Other languages
English (en)
Japanese (ja)
Other versions
JP7317805B2 (ja
JP2020522566A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/033376 external-priority patent/WO2018213697A1/en
Publication of JP2020522566A publication Critical patent/JP2020522566A/ja
Publication of JP2020522566A5 publication Critical patent/JP2020522566A5/ja
Priority to JP2023061093A priority Critical patent/JP7781815B2/ja
Application granted granted Critical
Publication of JP7317805B2 publication Critical patent/JP7317805B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020514147A 2017-05-19 2018-05-18 フォン・ヴィレブランド因子に関連する合併症及び障害の処置のための組成物及び方法 Active JP7317805B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023061093A JP7781815B2 (ja) 2017-05-19 2023-04-05 フォン・ヴィレブランド因子に関連する合併症及び障害の処置のための組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762508530P 2017-05-19 2017-05-19
US62/508,530 2017-05-19
US201862638579P 2018-03-05 2018-03-05
US62/638,579 2018-03-05
PCT/US2018/033376 WO2018213697A1 (en) 2017-05-19 2018-05-18 Compositions and methods for the treatment of complications and disorders relating to von willebrand factor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023061093A Division JP7781815B2 (ja) 2017-05-19 2023-04-05 フォン・ヴィレブランド因子に関連する合併症及び障害の処置のための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2020522566A JP2020522566A (ja) 2020-07-30
JP2020522566A5 true JP2020522566A5 (enExample) 2021-05-20
JP7317805B2 JP7317805B2 (ja) 2023-07-31

Family

ID=64274836

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020514147A Active JP7317805B2 (ja) 2017-05-19 2018-05-18 フォン・ヴィレブランド因子に関連する合併症及び障害の処置のための組成物及び方法
JP2023061093A Active JP7781815B2 (ja) 2017-05-19 2023-04-05 フォン・ヴィレブランド因子に関連する合併症及び障害の処置のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023061093A Active JP7781815B2 (ja) 2017-05-19 2023-04-05 フォン・ヴィレブランド因子に関連する合併症及び障害の処置のための組成物及び方法

Country Status (11)

Country Link
US (3) US11060094B2 (enExample)
EP (1) EP3624801A4 (enExample)
JP (2) JP7317805B2 (enExample)
KR (1) KR102830459B1 (enExample)
CN (2) CN117487811A (enExample)
AU (1) AU2018269935B2 (enExample)
CA (1) CA3058001A1 (enExample)
IL (1) IL269641B2 (enExample)
MX (1) MX390865B (enExample)
TW (1) TWI806868B (enExample)
WO (1) WO2018213697A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022015326A2 (pt) * 2020-02-04 2022-10-11 Takeda Pharmaceuticals Co Tratamento de menorragia em pacientes com doença de von willebrand severa por administração de vwf recombinante
US20230038761A1 (en) * 2020-02-04 2023-02-09 Band Therapeutics, Llc Regulation of von willebrand factor (vwf)
WO2022115502A1 (en) * 2020-11-24 2022-06-02 Band Therapeutics, Llc Compositions and methods for treatment of bleeding disorders
CN116723863A (zh) * 2020-11-24 2023-09-08 邦德治疗有限公司 用于治疗出血性病症的组合物和方法
US12090243B2 (en) 2021-03-24 2024-09-17 Aleo Bme, Inc. Compositions comprising fluid gels for tissue separation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008512098A (ja) * 2004-09-07 2008-04-24 アーケミックス コーポレイション フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
US7563601B1 (en) * 2005-06-01 2009-07-21 City Of Hope Artificial riboswitch for controlling pre-mRNA splicing
WO2008066621A2 (en) * 2006-10-19 2008-06-05 Duke University Reversible platelet inhibition
WO2008150495A2 (en) 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
WO2010091396A2 (en) * 2009-02-09 2010-08-12 Archemix Corp. Aptamers to von willerbrand factor and their use as thrombotic, hematologic and cardiovascular disease therapeutics
US20170044545A1 (en) * 2014-04-24 2017-02-16 Ribomic Inc. Aptamer for bonding to autotaxin and inhibiting biological activity of autotaxin, and use for same
EP3266871B1 (en) * 2015-03-06 2021-04-28 TAGCyx Biotechnologies Inc. Method for stabilizing dna aptamers
US10760083B2 (en) 2015-10-30 2020-09-01 Tagcyx Biotechnologies Inc. DNA aptamer that binds to vWF
US20230038761A1 (en) * 2020-02-04 2023-02-09 Band Therapeutics, Llc Regulation of von willebrand factor (vwf)
WO2022115502A1 (en) * 2020-11-24 2022-06-02 Band Therapeutics, Llc Compositions and methods for treatment of bleeding disorders
WO2023039522A1 (en) * 2021-09-10 2023-03-16 Guardian Therapeutics, Llc Fatty acid conjugates of nucleic acids

Similar Documents

Publication Publication Date Title
JP2023513502A5 (enExample)
JP2022084940A5 (enExample)
JP2018522563A5 (enExample)
AU2017202919B2 (en) Pegylated Apelin and uses thereof
JP2012529296A5 (enExample)
CA2984498C (en) Compositions and methods for inhibiting gene expression of hif2alpha
JP7291418B2 (ja) Ｐｃｓｋ９を標的としたアンチセンス核酸
JP2018515101A5 (enExample)
KR20220024192A (ko) 변형된 갭머 올리고뉴클레오타이드 및 사용 방법
JP2005532332A5 (enExample)
JP2008521840A5 (enExample)
HUE032125T2 (en) Preparation containing encapsulated antagomir
JP2024511954A (ja) ペプチド－オリゴヌクレオチド複合体を用いる筋強直性ジストロフィー１型の治療法
EP2701723B1 (en) Dna aptamers for promoting remyelination
US20190071670A1 (en) Methods Of Treatment For Alpha-1 Antitrypsin Deficiency
WO2003059382A2 (en) Pharmaceutical compositions comprising polyanionic polymers and amphiphilic block copolymers and methods of use thereof to improve gene expression
RU2001124840A (ru) Противоопухолевые антисмысловые последовательности, направленные на компоненты r1 и r2 рибонуклеотидредуктазы
JP2020517632A5 (enExample)
US7619066B2 (en) IL-1ra variants
JP2018521086A5 (enExample)
WO2021030326A1 (en) Brush polymers for therapeutic applications
US20120177594A1 (en) Polyion complex comprising phd2 expression inhibiting substance
JP2004538272A5 (enExample)
US20140171368A1 (en) Polyanion nanocomplexes for therapeutic applications
US9938533B2 (en) DNA aptamers specific to CD200R1 and their therapeutic uses